Herbst, Ronald

HMGB1 and RAGE in Inflammation and Cancer

Sims, G. P., Rowe, D. C., Rietdijk, S. T., Herbst, R., & Coyle, A. J. (2010) · Annual Review of Immunology

Advanced Glycation End Products researchImmune Response and Inflammation

Cited by 1,436

Microglia-dependent synapse loss in type I interferon-mediated lupus

Bialas, A. R., Presumey, J., Das, A., van der Poel, C. E., Lapchak, P. H., Mesin, L., Victora, G., Tsokos, G. C., Mawrin, C., Herbst, R., et al. (2017) · Nature

Systemic Lupus Erythematosus ResearchNeuroinflammation and Neurodegeneration Mechanisms

Cited by 197

Selective Targeting of TGF-β Activation to Treat Fibroinflammatory Airway Disease

Minagawa, S., Lou, J., Seed, R. I., Cormier, A., Wu, S., Cheng, Y., Murray, L., Tsui, P., Connor, J., Herbst, R., et al. (2014) · Science Translational Medicine

Cell Adhesion Molecules ResearchChronic Obstructive Pulmonary Disease (COPD) Research

Cited by 90

Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional STK11 Mutations in Patients with Non–Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown

Pore, N., Wu, S., Standifer, N., Jure-Kunkel, M., de los Reyes, M., Shrestha, Y., Halpin, R., Rothstein, R., Mulgrew, K., Blackmore, S., et al. (2021) · Cancer Discovery

Cancer Immunotherapy and BiomarkersLung Cancer Treatments and Mutations

Cited by 88

Targeting ADAM17 inhibits human colorectal adenocarcinoma progression and tumor‐initiating cell frequency

Dosch, J., Ziemke, E., Wan, S., Luker, K., Welling, T., Hardiman, K., Fearon, E., Thomas, S., Flynn, M., Rios-Doria, J., et al. (2017) · Oncotarget

Protease and Inhibitor MechanismsCancer Cells and Metastasis

Cited by 40